Tick Borne Encephalitis Clinical Trial
Official title:
Clinical Study to Test the Immunogenicity of Variant Schedules for TBE Rapid Immunisation Using Inactivated TBE (FSME) Vaccine
The study aims to answer this question: whether adequate immunity can be achieved in a short time, that is, by a rapid immunisation process, using at least one of 3 new TBE immunisation schedules? The investigators will test the immunogenicity (the degree of immunity achieved) of each of the immunisation schedules at various times after the injections. If the results of this clinical study are positive, it may then be possible to develop the most successful immunisation schedule so that it can be used routinely. This means that the results of the clinical study have an enormous practical value in preventing TBE in people travelling or moving into areas with a high TBE risk.
The data from at least 99 individuals will be needed if the study is to draw reliable
conclusions. One-third of these individuals will receive 3 injections in all: 2 on the first
day and the third injection 4 days later (immunisation schedule 1). Another one-third will
receive 2 injections in all: one on the first day and one injection 4 days later
(immunisation schedule 2). The remaining one-third will also receive 2 injections, both of
these on the first day (immunisation schedule 3). Participants will be assigned completely
randomly (by chance) to one of these three groups. So each participant stands a 33% chance
(a 1:2 chance) of receiving any one particular immunisation schedule. If you agree to take
part, the process will be as follows:
Brief Overview of the Course of the Clinical Study:
Vaccination scheme 1
Vaccination scheme 2
Vaccination scheme 3
Vaccinations:
I = Vaccination with FSME-IMMUN 0,5ml
- Scheme 1: 2 vaccinations at U1 (day 0), one injection into the left and the right upper
arm each, 1 vaccination at U2 (day 4), injection into the left upper arm
- Scheme 2: one vaccination at U1 (day 0) and at U2 (day 4), injections into the left
upper arm each
- Scheme 3: 2 vaccinations at U1 (day 0), one injection into the left and the right upper
arm each
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03956446 -
Tick-borne Encephalitis and Borrelial Antibodies in Serum
|
N/A | |
Completed |
NCT01562444 -
Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
|
Phase 4 | |
Completed |
NCT01991067 -
Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
|
Phase 2 | |
Completed |
NCT03958058 -
Tick-borne Encephalitis and Possible Borrelial Serology
|
||
Active, not recruiting |
NCT04017052 -
Application of a TBE-Vaccine in Obese Persons
|
Phase 4 |